260 related articles for article (PubMed ID: 21315119)
21. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
[TBL] [Abstract][Full Text] [Related]
22. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy.
Wu XL; Kim JH; Koo H; Bae SM; Shin H; Kim MS; Lee BH; Park RW; Kim IS; Choi K; Kwon IC; Kim K; Lee DS
Bioconjug Chem; 2010 Feb; 21(2):208-13. PubMed ID: 20073455
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.
Ryan GM; Kaminskas LM; Kelly BD; Owen DJ; McIntosh MP; Porter CJ
Mol Pharm; 2013 Aug; 10(8):2986-95. PubMed ID: 23750747
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
Kaminskas LM; McLeod VM; Ryan GM; Kelly BD; Haynes JM; Williamson M; Thienthong N; Owen DJ; Porter CJ
J Control Release; 2014 Jun; 183():18-26. PubMed ID: 24637466
[TBL] [Abstract][Full Text] [Related]
25. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
26. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes.
Upadhyay KK; Bhatt AN; Mishra AK; Dwarakanath BS; Jain S; Schatz C; Le Meins JF; Farooque A; Chandraiah G; Jain AK; Misra A; Lecommandoux S
Biomaterials; 2010 Apr; 31(10):2882-92. PubMed ID: 20053435
[TBL] [Abstract][Full Text] [Related]
27. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
28. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Han L; Huang R; Li J; Liu S; Huang S; Jiang C
Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
[TBL] [Abstract][Full Text] [Related]
29. Cell-targeted, dual reduction- and pH-responsive saccharide/lipoic acid-modified poly(L-lysine) and poly(acrylic acid) polyionic complex nanogels for drug delivery.
How SC; Chen YF; Hsieh PL; Wang SS; Jan JS
Colloids Surf B Biointerfaces; 2017 May; 153():244-252. PubMed ID: 28267669
[TBL] [Abstract][Full Text] [Related]
30. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
[TBL] [Abstract][Full Text] [Related]
31. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Li Y; He H; Jia X; Lu WL; Lou J; Wei Y
Biomaterials; 2012 May; 33(15):3899-908. PubMed ID: 22364698
[TBL] [Abstract][Full Text] [Related]
32. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
[TBL] [Abstract][Full Text] [Related]
33. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
Wang K; Zhang X; Zhang L; Qian L; Liu C; Zheng J; Jiang Y
Drug Deliv; 2015 May; 22(3):389-99. PubMed ID: 24670095
[TBL] [Abstract][Full Text] [Related]
34. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
35. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
36. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
37. [The Combined Effects of Ionizing Radiation and Dendritic Polymers Loaded with Doxorubicin on the MCF-7 Breast Cancer Cell Line].
Zamulaeva IA; Pronyushkina KA; Matchuk ON; Yabbarov NG; Nikolskaya ED; Kondrasheva IG
Radiats Biol Radioecol; 2015; 55(6):591-7. PubMed ID: 26964344
[TBL] [Abstract][Full Text] [Related]
38. Poly(ethylene glycol)-modified PAMAM-Fe3O4-doxorubicin triads with the potential for improved therapeutic efficacy: generation-dependent increased drug loading and retention at neutral pH and increased release at acidic pH.
Nigam S; Chandra S; Newgreen DF; Bahadur D; Chen Q
Langmuir; 2014 Feb; 30(4):1004-11. PubMed ID: 24446987
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
Lee ES; Na K; Bae YH
J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
[TBL] [Abstract][Full Text] [Related]
40. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
